HGSI » Topics » General

This excerpt taken from the HGSI DEF 14A filed Mar 24, 2009.
General
 
The purpose of the ESPP is to promote our success and enhance our value by providing eligible employees with the opportunity to purchase Common Stock at a discount through payroll deductions. We intend the ESPP to qualify as an “employee stock purchase plan” under Section 423 of the Internal Revenue Code.
 
The ESPP, as initially approved by our stockholders in 2000, authorized eligible employees to purchase up to 500,000 shares of our Common Stock. The ESPP was amended and restated in 2007 to provide an additional 500,000 shares of our Common Stock for purchase under the ESPP. Since the ESPP’s inception, we have issued 955,441 of such shares and 44,559 remain available for future purchase. Through this amendment and restatement of the ESPP, an additional 1,000,000 shares are being made available for purchase. Note that we will adjust the number of shares available for purchase under the ESPP for stock dividends, stock splits, reclassifications, and other changes affecting our Common Stock. The shares available for purchase under the ESPP may, in the Board of Directors’ discretion, be authorized but unissued shares of our Common Stock, shares purchased on the open market, or shares derived from any other proper source.
 
This excerpt taken from the HGSI DEF 14A filed Mar 25, 2008.
General
 
This Proxy Statement is being furnished to stockholders of Human Genome Sciences, Inc., a Delaware corporation (the “Company”, “we”, “us”, or “our”), in connection with the solicitation by the Board of Directors of proxies for use at the Annual Meeting of Stockholders (the “Annual Meeting”) to be held at the University System of Maryland — Shady Grove Center, Germantown Room, 9630 Gudelsky Drive, Rockville, Maryland 20850 on Wednesday, May 7, 2008 at 9:30 a.m., local time, and at any adjournment or postponement thereof.
 
This excerpt taken from the HGSI DEF 14A filed Mar 21, 2007.
General
 
The purpose of the ESPP is to promote our success and enhance our value by providing eligible employees with the opportunity to purchase Common Stock at a discount through payroll deductions. Stock ownership increases our employees’ stake in our success and encourages them to remain with us. We intend the ESPP to qualify as an “employee stock purchase plan” under Section 423 of the Internal Revenue Code.
 
The ESPP, as initially approved by our stockholders in 2000, authorized eligible employees to purchase up to 500,000 shares of our Common Stock. Since the ESPP’s inception, we have issued 475,540 of such shares and 24,460 remain available for future purchase. Through this amendment and restatement of the ESPP, 500,000 additional shares are being made available for purchase. Note that we will adjust the number of shares available for purchase under the ESPP for stock dividends, stock splits, reclassifications, and other changes affecting our Common Stock. The shares available for purchase under the ESPP may, in the Board of Directors’ discretion, be authorized but unissued shares of our Common Stock, shares purchased on the open market, or shares derived from any other proper source.
 
This excerpt taken from the HGSI DEF 14A filed Mar 22, 2006.
General
 
This Proxy Statement is being furnished to stockholders of Human Genome Sciences, Inc., a Delaware corporation (the “Company”), in connection with the solicitation by the Board of Directors of proxies for use at the Annual Meeting of Stockholders (the “Annual Meeting”) to be held in Room F at the Gaithersburg Marriott, 9751 Washingtonian Boulevard, Gaithersburg, Maryland 20878 on Wednesday, April 26, 2006 at 9:30 a.m., local time, and at any adjournment or postponement thereof.
 
This excerpt taken from the HGSI 10-K filed Mar 15, 2005.
General. We face intense competition from a wide range of pharmaceutical, biotechnology and diagnostic companies, as well as academic and research institutions and government agencies. Some of these competitors have substantially greater financial, marketing, research and development and human resources. Most large pharmaceutical companies have considerably more experience in undertaking clinical trials and in obtaining regulatory approval to market pharmaceutical products.

     

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki